Dr. Wilson is a pharmaceutical industry veteran with over 25 years of small molecule chemistry, manufacturing and control experience. Prior to joining Aptuit, Dr. Wilson served as Vice President of Pharmaceutical Operations at Vertex Pharmaceuticals. There he built a large multi-disciplinary CMC Development group which included process chemistry, formulation development, analytical development, physical sciences, quality assurance, project management and Quality by-Design CMC processes. Before joining Vertex, Dr. Wilson held a number management and technical roles at Glaxo and Burroughs Wellcome where he led the multidisciplinary teams that developed manufacturing processes for the HIV therapies AZT and abacavir. Dr. Wilson earned his B.S. degree in Chemistry at the University of New Hampshire and his Ph.D. at Duke University.
Dr Wilson will lead the small molecule CMC practice area for Aptuit Consulting and can be reached at (617) 943-4703.
“We are pleased to welcome Jeff to Aptuit Consulting” said Mr. Griffith, President and CEO of Aptuit. “Jeff has a distinguished track record within industry leading both biotech and large pharma organizations. His extensive CMC experience further broadens the level of technical, regulatory and strategic drug development expertise Aptuit Consulting can provide to our customers.”
Aptuit Consulting Inc., an Aptuit company, is an independent, global, pharmaceutical, medical device and intellectual property consultancy, that supports product development needs of clients. Our consultants have deep experience with worldwide regulatory authority requirements in all therapeutic fields. Practice areas include: Strategic Planning, CMC, Preclinical, Clinical, Legal/IP and Regulatory Submissions. For more information please visit our website at www.aptuitconsulting.com or call 781-778-0418.
